Wordt geladen...
Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels
Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
S. Karger AG
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3901587/ https://ncbi.nlm.nih.gov/pubmed/24474924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000357211 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|